全文获取类型
收费全文 | 64439篇 |
免费 | 6353篇 |
国内免费 | 2417篇 |
专业分类
耳鼻咽喉 | 435篇 |
儿科学 | 525篇 |
妇产科学 | 665篇 |
基础医学 | 4889篇 |
口腔科学 | 3501篇 |
临床医学 | 9193篇 |
内科学 | 4987篇 |
皮肤病学 | 554篇 |
神经病学 | 2157篇 |
特种医学 | 3010篇 |
外国民族医学 | 8篇 |
外科学 | 5900篇 |
综合类 | 13617篇 |
现状与发展 | 6篇 |
一般理论 | 3篇 |
预防医学 | 6959篇 |
眼科学 | 1051篇 |
药学 | 6819篇 |
47篇 | |
中国医学 | 6126篇 |
肿瘤学 | 2757篇 |
出版年
2024年 | 158篇 |
2023年 | 1609篇 |
2022年 | 2801篇 |
2021年 | 3619篇 |
2020年 | 3526篇 |
2019年 | 1941篇 |
2018年 | 1930篇 |
2017年 | 1442篇 |
2016年 | 1816篇 |
2015年 | 2273篇 |
2014年 | 4963篇 |
2013年 | 4723篇 |
2012年 | 6684篇 |
2011年 | 6400篇 |
2010年 | 4540篇 |
2009年 | 3970篇 |
2008年 | 2653篇 |
2007年 | 3275篇 |
2006年 | 2680篇 |
2005年 | 1793篇 |
2004年 | 1645篇 |
2003年 | 1510篇 |
2002年 | 1354篇 |
2001年 | 1305篇 |
2000年 | 806篇 |
1999年 | 842篇 |
1998年 | 603篇 |
1997年 | 587篇 |
1996年 | 371篇 |
1995年 | 219篇 |
1994年 | 207篇 |
1993年 | 204篇 |
1992年 | 235篇 |
1991年 | 194篇 |
1990年 | 176篇 |
1989年 | 68篇 |
1988年 | 42篇 |
1987年 | 26篇 |
1986年 | 9篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1982年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
81.
82.
《Seminars in diagnostic pathology》2020,37(6):273-282
While the lung is frequently involved by systemic lymphoma, primary pulmonary lymphoma accounts for less than 1% of all extranodal ymphomas. In particular, T-cell lymphoma is very rare in the lung, as a primary or secondary lesion. Patients with pulmonary T-cell lymphoma usually present with cough, dyspnea, pain, fever, recurrent infections, and hemoptysis. Typical radiologic features include pulmonary nodules, consolidation, solid pulmonary opacities, cystic changes, hilar adenopathy, and pleural effusions. Patients with these clinical and radiologic findings are frequently presumed to have pneumonia and initially treated with empirical antibiotics. Therefore, CT-guided needle biopsy, bronchoscopic examination, or even wedge biopsy should be considered when clinical symptoms show deterioration despite adequate antibiotic therapy. Precise pathologic diagnosis and molecular characterization are recommended in all cases, following the World Health Organization (WHO) classification. Principles of treatment typically vary with the different histologic types of T-cell lymphoma. 相似文献
83.
目的对膝关节前外侧韧带(anterolateral ligament,ALL)的研究进展进行综述,为临床诊治提供参考。方法广泛查阅近年来国内外有关 ALL 损伤诊断及治疗的文献,总结膝关节 ALL 解剖形态、生物力学以及 ALL 损伤机制、治疗现状。结果膝关节 ALL 具有限制胫骨内旋及前移作用,影响膝关节轴移。ALL 损伤后可结合患者体征和 MRI 检查诊断。膝关节 ALL 手术指征尚未统一,但多数学者倾向于对需进行前交叉韧带(anterior cruciate ligament,ACL)重建或翻修且伴有高度轴移试验阳性的患者进行 ALL 重建。目前 ALL 重建方式较多,但尚无最佳治疗术式。此外,由于缺乏高质量的术后长期随访研究,远期临床疗效仍不明确。结论ALL 在维持膝关节稳定性方面具有一定作用,但 ALL 重建技术及临床疗效仍待进一步研究。 相似文献
84.
85.
86.
目的 探讨营养风险与腹膜后肿瘤患者住院时间的相关性。方法 采用回顾性研究,选取2012年1月至2018年12月四川大学华西医院血管外科新入院腹膜后肿瘤患者60例,采用营养风险筛查表评估患者营养风险,收集患者体质指数、围术期血红蛋白和白蛋白水平、住院天数、术后恶心呕吐发生情况、术后排气、排便时间和首次进食时间。采用单因素分析比较不同患者住院时间,采用多重线性逐步回归分析患者住院时间的影响因素。结果 纳入的60例腹膜后肿瘤患者中,40例患者(66.7%)术前存在营养风险,52例患者(86.7%)术后存在营养风险;单因素分析显示,患者术前、术后营养风险 (术前P<0.001,术后P=0.043)、术前白蛋白 (P=0.019)、术后血红蛋白 (P=0.019)、术后白蛋白(P=0.025) 水平以及术后恶心呕吐 (P=0.001) 均会影响患者的住院时间;患者住院时间与围术期营养风险筛查工具评分、术后首次进食时间、术后排气时间和排便时间具有相关性,且相关性强(r=0.759~0.770; P<0.01);多因素分析显示术前营养风险是腹膜后肿瘤患者住院时间的重要预测因素(β=0.399)。结论 术前营养风险是腹膜后肿瘤患者住院时间的预测因子。 相似文献
87.
88.
89.
Jinlan He Jianxiong He Li Min Yan He Hui Guan Jingjing Wang Xingchen Peng 《International journal of cancer. Journal international du cancer》2020,146(4):1052-1063
Sorafenib provides survival benefits in patients with advanced renal cell carcinoma (RCC), but its use is hampered by acquired drug resistance. It is important to fully clarify the molecular mechanisms of sorafenib resistance, which can help to avoid, delay or reverse drug resistance. Extracellular vesicles (EVs) can mediate intercellular communication by delivering effector molecules between cells. Here, we studied whether EVs are involved in sorafenib resistance of RCC and its possible molecular mechanisms. Using differential centrifugation, EVs were isolated from established sorafenib-resistant RCC cells (786-0 and ACHN), and EVs derived from sorafenib-resistant cells were uptaken by sensitive parental RCC cells and thus promoted drug resistance. Elevated exogenous miR-31-5p within EVs effectively downregulated MutL homolog 1 (MLH1) expression and thus promoted sorafenib resistance in vitro. Mice experiments also confirmed that miR-31-5p could mediate drug sensitivity in vivo. In addition, low expression of MLH1 was observed in sorafenib-resistant RCC cells and upregulation of MLH1 expression restored the sensitivity of resistant cell lines to sorafenib. Finally, miR-31-5p level in circulating EVs of RCC patients with progressive disease (PD) during sorafenib therapy was higher when compared to that in the pretherapy status. In conclusion, EVs shuttled miR-31-5p can transfer resistance information from sorafenib-resistant cells to sensitive cells by directly targeting MLH1, and thus magnify the drug resistance information to the whole tumor. Furthermore, miR-31-5p and MLH1 could be promising predictive biomarkers and therapeutic targets to prevent sorafenib resistance. 相似文献
90.
《Neuropeptides》2015
The neuropeptide galanin is widely expressed in both the central and peripheral nervous systems. However there is limited understanding of how individual galanin receptor (GalR1, 2, and 3) subtypes mediate the physiological activity of galanin in vivo. To address this issue we utilized NAX-5055, a systemically available, metabolically stable galanin analog. NAX-5055 displays a preference for GalR1 receptors and possesses potent anticonvulsant activity in vivo, suggesting that NAX-5055 engages central galanin receptors. To determine if NAX-5055 also modulates the activity of peripheral galanin receptors, we evaluated the effect of NAX-5055 on blood glucose and insulin levels in mice. Acute and repeated (once daily for four days) systemic administration of NAX-5055 (4 mg/kg) significantly increased blood glucose levels compared to vehicle treated mice. However, a hyperglycemic response was not observed following systemic administration of NAX-805-1, a scrambled analog of NAX-5055, with critical receptor binding residues, Trp2 and Tyr9, reversed. These results suggest that chemical modifications independent of the galanin backbone of NAX-5055 are not responsible for the hyperglycemic response. The effect of NAX-5055 on glucose homeostasis was further evaluated with a glucose tolerance test (GTT). Mice administered either acute or repeated (once daily for four days) injections of NAX-5055 (4 mg/kg) displayed impaired glucose handling and reduced insulin response to an acute glucose (1g/kg) challenge. Here we have shown that systemic administration of a centrally active GalR1-preferring galanin analog produces acute hyperglycemia and an inhibition of insulin release in vivo and that these effects are not attenuated with repeated administration. NAX-5055 thus provides a new pharmacological tool to further the understanding of function of both central and peripheral GalR1 receptors in vivo. 相似文献